As such, high intracellular THEMIS2 concentration, as measured by clinically applicable techniques such as ELISA, could be putatively positioned as biomarker of poor prognosis in early-stage CLL, complementary to IGHV and TP53 mutational profiling. Here, THEMIS2 is linked to B-cell chronic lymphocytic leukemia.